Leukemia  >>  GEM 640  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GEM 640 / Pharmascience
NCT01018069 / 2009-013669-25: AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Terminated
2
60
US, Canada, Europe
AEG35156
Aegera Therapeutics
Leukemia
10/10
10/10
NCT00363974: Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Completed
1/2
54
US, Canada
XIAP antisense
Aegera Therapeutics
Leukemia, Myelomonocytic, Acute
03/09
03/09
NCT00768339: A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Terminated
1/2
25
US, Canada
AEG35156 antisense IV infusion, XIAP antisense
Aegera Therapeutics, The Leukemia and Lymphoma Society
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
06/11
09/11

Download Options